Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Metronomic Capecitabine with Aromatase Inhibitors in Metastatic Breast Cancer
Randomized, open-label, phase 3 trial (MECCA) HR+/HER2- metastatic breast cancer, treatment-naive in metastatic setting Metronomic capecitabine (500 mg TID continuously) + AI vs. A
New Reference: Botensilimab / Balstilimab for Metastatic Sarcomas
Phase 1, open-label, multicenter study (C-800-01) Patients with relapsed/refractory metastatic sarcomas Botensilimab (1 or 2 mg/kg IV Q6W) + Balstilimab (3 mg/kg IV Q2W) for up to
New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations
Open-label, randomized, multicenter phase 3 trial (ACHILLES/TORG1834) Previously untreated non-squamous NSCLC with sensitizing uncommon EGFR mutations (excluding exon20ins and T790
New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations
Phase II, single-arm, open-label study (TROPION-Lung05) Advanced/metastatic NSCLC with actionable genomic alterations Datopotamab deruxtecan 6mg/kg Q3W
New Reference: Sacituzumab Govitecan for Advanced Urothelial Carcinoma
Phase 3, randomized, open-label trial (TROPiCS-04) Previously treated advanced urothelial carcinoma (progression after platinum-based chemotherapy and checkpoint inhibitor) Sacituz
New Reference: Ipilimumab / Nivolumab for Non-Clear Cell RCC
Phase 2, multicenter, randomized trial (SUNNIFORECAST) Previously untreated advanced/metastatic non-clear cell RCC Ipilimumab + nivolumab (4 cycles) followed by nivolumab maintenan
New Reference: Neoadjuvant FOLFIRNOX for Pancreatic Cancer
Multicenter, randomized, noncomparative phase 2 trial (PANACHE01 FRENCH08 PRODIGE48) Resectable pancreatic adenocarcinoma patients Neoadjuvant mFOLFIRINOX (4 cycles) vs. neoadjuvan
New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma
Multicentre, open-label, phase 1–2 study (MonumenTAL-1) Relapsed/refractory multiple myeloma pts with ≥3 prior lines of therapy Talquetamab 0.4 mg/kg weekly or 0.8 mg/kg every
New Reference: SOX for Gastric/GEJ AdenoCa
Open-label, randomized, phase 3 trial (RESOLVE) Patients with cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma after D2 gastrectomy Perioperative SO
